StockNews.com started coverage on shares of NanoViricides (NYSE:NNVC – Free Report) in a research report report published on Wednesday morning. The brokerage issued a sell rating on the stock.
NanoViricides Stock Down 5.8 %
Shares of NNVC stock opened at $1.13 on Wednesday. The firm has a fifty day moving average of $1.20 and a 200-day moving average of $1.16. The firm has a market capitalization of $13.31 million, a price-to-earnings ratio of -1.40 and a beta of 0.70. NanoViricides has a 12-month low of $1.00 and a 12-month high of $2.00.
NanoViricides (NYSE:NNVC – Get Free Report) last released its quarterly earnings results on Wednesday, February 14th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.01.
About NanoViricides
NanoViricides, Inc, a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases.
See Also
- Five stocks we like better than NanoViricides
- Market Cap Calculator: How to Calculate Market Cap
- Appleās Earnings Show Investors Its Strength and Its Weakness
- Stock Average Calculator
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
- 3 Tickers Leading a Meme Stock Revival
- DraftKings Q1: Strong Customer Acquisition and Product Innovation
Receive News & Ratings for NanoViricides Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoViricides and related companies with MarketBeat.com's FREE daily email newsletter.